Does Mica Antigen Influence on Cellular and Vascular Rejection in Kidney Transplantation?

Kato, Masashi; Kinukawa, Tsuneo; Hattori, Reiko; Tsuji, Yukiko; Tsuyuki, Mikito; Kohriyama, N

doi:10.1097/01.tp.0000331680.06947.e1

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The case highlights the need for including regular MICA antibody screening in the pretransplant work‐up. Similar results have been published by other investigators, highlighting the role of pretransplant donor‐specific MICA antibodies on the development of acute rejection …”

Section: Immunobiology Of Transplantationsupporting

confidence: 90%

“…Similar results have been published by other investigators, highlighting the role of pretransplant donor-specific MICA antibodies on the development of acute rejection. 87,88 Antibody removal therapy Current strategies used for prevention and treatment of antibody-mediated graft damage include (1) antibody removal and neutralization through plasmapheresis, immunoadsorption, intravenous immunoglobulin (IVIG) infusion, and splenectomy, (2) inhibition of B cell proliferation by using potent immunomodulatory agents that include Mycophenolate mofetil, rituximab, IVIG, and splenectomy, (3) proteasome-based plasma cell inhibitors like bortezomib, (4) T cell depleting agents that include antithymocyte globulin (ATG), (5) conversion to tacrolimus-based regimens, and (6) inhibition of complement pathway, for example, through blockage of the C5 component use of eculizumab. Of these, IVIG is the most commonly used strategy either alone or in combination with plasmapheresis.…”

Section: Major Histocompatibility Complex Class I-related Chain Amentioning

confidence: 99%

See 1 more Smart Citation

Clinical relevance of antibody development in renal transplantation

Mehra

Siddiqui

Baranwal

et al. 2013

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The detection and characterization of anti-HLA antibodies and the clinical impact of their appearance following renal transplantation are areas of immense interest. In particular, de novo development of donor-specific antibodies (DSA) has been associated with acute and chronic antibody-mediated graft rejection (AMR). Recently, methods for antibody detection have evolved remarkably from conventional cell-based assays to advanced solid phase systems. These systems have revolutionized the art of defining clinically relevant antibodies that are directed toward a renal graft. While anti-HLA DSAs have been widely associated with poor graft survival, the role of non-HLA antibodies, particularly those directed against endothelial cells, is beginning to be realized. Appreciation of the mechanisms underlying T cell recognition of alloantigens has generated great interest in the use of synthetic peptides to prevent graft rejection. Hopefully, continued progress in unraveling the molecular mechanisms of graft rejection and posttransplant monitoring of antibodies using highly sensitive testing systems will prove beneficial to immunological risk assessment and early prediction of renal allograft failure.

show abstract

Section: Immunobiology Of Transplantationsupporting

confidence: 90%

Section: Major Histocompatibility Complex Class I-related Chain Amentioning

confidence: 99%